Treating Angina Pectoris in Hypertension

  • Hal L. Chadow
  • Joel A. Strom
Part of the Current Clinical Practice book series (CCP)


It is estimated that 13.5 million people in the United States have ischemic heart disease (IHD), and 1.5 million new cases are diagnosed each year. IHD remains the leading cause of mortality, resulting in approx 500,000 deaths annually. Many studies have identified specific risk factors for coronary artery disease (CAD). These include a family history, diabetes mellitus, hypertension, hyperlipidemia, and smoking. The incidence of cardiovascular events increases with the number of risk factors present and is greater than would be predicted by their combined presence. Primary and secondary prevention including effective blood pressure (BP) control and lowering of serum cholesterol levels, together with significant strides in the treatment of IHD, have resulted in significant reductions in morbidity and mortality. In this chapter, we review the management of the hypertensive patient with IHD.


Heart Outcome Prevention Evaluation Study Recurrent Cardiovascular Event Antianginal Medication Percutaneous Trans Luminal Coronary Angioplasty Nitrate Nitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360.Google Scholar
  2. 2.
    Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA (1994) Unstable Angina: Diagnosis and Management. Clinical practice guideline number 10. Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, United States Department of Health and Human Services.Google Scholar
  3. 3.
    Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ (1998) Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98: 2829–2835.PubMedCrossRefGoogle Scholar
  4. 4.
    Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB, McCallister BD, Smith SC, Ullyot DJ (1993) Guidelines for percutaneous transluminal coronary angioplasty: a report from the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (committee on percutaneous transluminal coronary angioplasty). JAm Coll Cardiol 22: 2033–2054.CrossRefGoogle Scholar
  5. 5.
    The EPIC investigators (1994) Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330: 956–961.Google Scholar
  6. 6.
    Antman E, Lau J, Kupelnick B, et al. (1992) A comparison of results of meta-analysis of randomized control trials and recommendations of clinical experts: treatment for myocardial infarction. JAMA 268: 240–248.PubMedCrossRefGoogle Scholar
  7. 7.
    Packer M, Bristow MR, Cohn JN, et al. (1996) The effect of carvedolol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (21): 1349–1355.PubMedCrossRefGoogle Scholar
  8. 8.
    Packer M, O’Connor CM, Ghali JK, et al., for the Prospective Randomized Amplodipine Survival Evaluation Study Group (1996) Effect of amplodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335(15): 1107–1114.Google Scholar
  9. 9.
    The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302.Google Scholar
  10. 10.
    The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153.Google Scholar
  11. 11.
    King SB III, Lembo NJ, Weintraub WS, et al. (1994) A randomized trial comparing angioplasty with coronary surgery: Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 331: 1044–1050.PubMedCrossRefGoogle Scholar
  12. 12.
    Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) (1997) Arch Intern Med 157: 2413–2446.Google Scholar
  13. 13.
    Adult Treatment Panel II: National Cholesterol Education Program (1994) Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 89: 1329–1445.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Hal L. Chadow
  • Joel A. Strom

There are no affiliations available

Personalised recommendations